High-Efficiency, DSB-Free Genome Engineering for Industrial Chassis Optimization. Bacillus subtilis is a premier "Gram-positive workhorse" for the production of industrial enzymes, vitamins, and biopharmaceuticals. However, traditional CRISPR-Cas9 methods often suffer from high lethality due to DNA double-strand breaks (DSBs). CD Biosynsis provides professional Bacillus subtilis Precision Base Editing Services, utilizing dCas9-fused deaminases to achieve highly efficient, scarless, and low-toxicity genetic modifications. Our platform is ideal for genome streamlining, multi-gene inactivation, and precision metabolic rewiring.
Request a QuoteOur platform provides a versatile range of base editing solutions, enabling precise nucleotide transitions (C-to-T or A-to-G) without the need for donor DNA or the risk of cell death from genomic cleavage.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Precision Base Editing | CRISPR-dCas9 Cytosine Deaminase | Single-nucleotide tuning & STOP-codon insertion | 2 Validated stocks + Sanger Report |
| Multiplex Genome Editing | "One-shot" Multi-gene Inactivation | Simultaneous deactivation of up to 8 genes | Engineered multi-knockout strains |
| PAM-less Engineering | PAM-independent BE Toolbox | Targets in PAM-deficient regions | Flexible customized mutants + Validation |
| Genome Streamlining | Large-scale Protease Deletion | Creating robust industrial chassis | Minimal-protease strains + WGS data |
1. Bioinformatic Design
2. Editor Selection
3. Multiplex Screening
4. Validation & Delivery
Target evaluation and sgRNA design focused on the 5 nt precision editing window.
Formal project proposal and Mutual NDA signing.
Selection of the appropriate base editor (CBE/ABE) or PAM-less variant based on the target locus.
Optimization of transformation protocols for specific B. subtilis strains.
"One-shot" deactivation and screening of high-performing mutants from combinatorial libraries.
High-throughput identification of successful multi-gene knockouts.
Plasmid curing and final verification via Sanger sequencing or Whole Genome Sequencing (WGS).
Final delivery of optimized strains and characterization reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. Please note that these studies represent established academic benchmarks and were not conducted by our company.
In industrial fermentation, reducing extracellular protease activity is vital for protein stability. Research utilizing CRISPR-dCas9 fused with cytosine deaminase has defined a 5 nt editing window with up to 100% efficiency. This system enables the simultaneous editing of 3 to 4 sites and has successfully deactivated eight extracellular protease genes in two rounds. This provides a powerful framework for genome streamlining in industrial strains without the toxicity of double-strand breaks.
(Reference: 2020 Study on CRISPR-dCas9 BE in B. subtilis)
Multiplex base editing allows for the "one-shot" deactivation of up to eight genes. While initially demonstrated in other species, this high-throughput technology has been adapted to B. subtilis for the rapid deactivation of biosynthetic pathways. This approach is instrumental in screening and identifying critical genes involved in the synthesis of novel antibiotics and secondary metabolites, effectively bypassing the limitations of sequential gene knockouts.
(Reference: 2022 Multiplex Base Editing Study)
Traditional CRISPR systems are restricted by the availability of specific Protospacer Adjacent Motif (PAM) sequences (e.g., NGG). The development of a PAM-less base editing toolbox in B. subtilis has greatly expanded the scope of genome engineering. This technical innovation allows for the precise modification of metabolic pathways even in PAM-deficient regions, leading to significantly improved yields of target metabolites such as vitamins and industrial enzymes.
(Reference: 2023 PAM-less Base Editing Toolbox Research)
1. How does base editing differ from standard CRISPR gene knockouts?
Standard CRISPR causes double-strand breaks that can be lethal to B. subtilis. Base editing uses a "dead" Cas9 (dCas9) to change specific nucleotides without cutting the DNA, resulting in higher survival rates and scarless results.
2. Can you target genes that do not have an NGG PAM sequence?
Yes. Our PAM-less base editing toolbox overcomes traditional sequence restrictions, allowing us to edit targets that were previously "un-editable" by standard CRISPR systems.
3. Is it possible to knock out multiple proteases in a single round?
Yes. Our multiplex system can deactivate 3 to 8 protease genes in a "one-shot" process, significantly speeding up the construction of minimal-protease industrial chassis.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.